| Literature DB >> 28842125 |
Yanfang Zhao1, Murugavel Ponnusamy1, Lei Zhang1, Yuan Zhang1, Cuiyun Liu1, Wanpeng Yu1, Kun Wang2, Peifeng Li3.
Abstract
Cardiovascular disease (CVD) is the leading cause of death throughout the world. The increase in new patients every year leads to a demand for the identification of valid and novel prognostic and diagnostic biomarkers for the prevention and treatment of cardiovascular diseases. MicroRNAs (miRNAs) are critical endogenous small noncoding RNAs that negatively modulate gene expression by regulating its translation. miRNAs are implicated in most physiological processes of the heart and in the pathological progression of cardiovascular diseases. miR-214 is a deregulated miRNA in many pathological conditions, and it contributes to the pathogenesis of multiple human disorders, including cancer and cardiovascular diseases. miR-214 has dual functions in different cardiac pathological circumstances. However, it is considered as a promising marker in the prognosis, diagnosis and treatment of cardiovascular diseases. In this review, we discuss the role of miR-214 in various cardiac disease conditions, including ischaemic heart diseases, cardiac hypertrophy, pulmonary arterial hypertension (PAH), angiogenesis following vascular injury and heart failure.Entities:
Keywords: Angiogenesis; Cardiac hypertrophy; Heart failure; Ischaemic heart diseases; MiR-214; Pulmonary arterial hypertension
Mesh:
Substances:
Year: 2017 PMID: 28842125 DOI: 10.1016/j.ejphar.2017.08.009
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432